MedPath

A clinical trial to evaluate the safety of nivolumab for relapsed or residual haematological cancers after blood or bone marrow transplantatio

Phase 1
Active, not recruiting
Conditions
Haematological malignancies
Cancer - Hodgkin's
Cancer - Leukaemia - Acute leukaemia
Cancer - Leukaemia - Chronic leukaemia
Registration Number
ACTRN12617000473369
Lead Sponsor
Melbourne Health
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Active, not recruiting
Sex
All
Target Recruitment
14
Inclusion Criteria

Age > 18 years
Prior allogeneic stem cell transplant for a haematological malignancy
Confirmed relapse or persistent haematological malignancy post allogeneic transplant
Immunosuppression cessation for minimum 2 weeks

Exclusion Criteria

Current evidence of any grade of GVHD
Prior history of grade 2 or higher acute GVHD
Moderate chronic GVHD within the previous 6 months or any prior history of severe chronic GVHD
Known autoimmune disease
Positive hepatitis B virus surface antigen
Positive hepatitis C virus antibody
Known HIV infection

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath